Dawidowski, M.* ; Król, M.* ; Szulczyk, B.* ; Chodkowski, A.* ; Podsadni, P.* ; Konopelski, P.* ; Ufnal, M.* ; Szuberski, P.* ; Wróbel, M.Z.* ; Zhang, Y.* ; El Harchi, A.* ; Hancox, J.C.* ; Jarkovska, D.* ; Mistrova, E.* ; Sviglerova, J.* ; Štengl, M.* ; Popowicz, G.M. ; Turło, J.*
Structure-activity relationship and cardiac safety of 2-aryl-2-(pyridin-2-yl) acetamides as a new class of broad-spectrum anticonvulsants derived from Disopyramide.
Bioorg. Chem. 98:103717 (2020)
A series of 2-aryl-2-(pyridin-2-yl)acetamides were synthesized and screened for their anticonvulsant activity in animal models of epilepsy. The compounds were broadly active in the 'classical' maximal electroshock seizure (MES) and subcutaneous Metrazol (scMET) tests as well as in the 6 Hz and kindling models of pharmacoresistant seizures. Furthermore, the compounds showed good therapeutic indices between anticonvulsant activity and motor impairment. Structure-activity relationship (SAR) trends clearly showed the highest activity resides in unsubstituted phenyl derivatives or compounds having ortho- and meta- substituents on the phenyl ring. The 2-aryl-2-(pyridin-2-yl)acetamides were derived by redesign of the cardiotoxic sodium channel blocker Disopyramide (DISO). Our results show that the compounds preserve the capability of the parent compound to inhibit voltage gated sodium currents in patch-clamp experiments; however, in contrast to DISO, a representative compound from the series 1 displays high levels of cardiac safety in a panel of in vitro and in vivo experiments.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Voltage-gated Sodium Channel ; Sodium Channel Blocker ; Disopyramide ; Drug Discovery ; Structure-activity Relationships ; Anticonvulsant Agent ; Refractory Epilepsy ; Drug Repositioning ; Medicinal Chemistry ; Cardiac Safety; Pharmacological Characterization; Antiarrhythmic-drugs; Antiepileptic Drugs; Qt Prolongation; Model; Inhibition; Discovery; Mediation; Quinidine; Epilepsy
Keywords plus
Language
english
Publication Year
2020
Prepublished in Year
HGF-reported in Year
2020
ISSN (print) / ISBN
0045-2068
e-ISSN
1090-2120
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 98,
Issue: ,
Pages: ,
Article Number: 103717
Supplement: ,
Series
Publisher
Elsevier
Publishing Place
San Diego, Calif.
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Enabling and Novel Technologies
PSP Element(s)
G-503000-001
Grants
Copyright
Erfassungsdatum
2020-05-08